Incyte Corp(INCY) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 4:53 PM ET (Korea 10/28 05:53)
Full metrics table
| Index | S&P 500 | P/E | 14.86 | EPS (ttm) | 7.85 | Insider Own | 0.91% | Shs Outstand | 201.0M | Perf Week | -0.01% |
| Market Cap | 23.63B | Forward P/E | 14.33 | EPS next Y | 172.89% | Insider Trans | -8.67% | Shs Float | 200.8M | Perf Month | -6.59% |
| Enterprise Value | 19.14B | PEG | 1.43 | EPS next Q | -3.93 | Inst Own | 103.7% | Short Float | 4.99% | Perf Quarter | -8.26% |
| Income | 1.61B | P/S | 4.06 | EPS this Y | -56.16% | Inst Trans | -1.04% | Short Ratio | 5.99 | Perf Half Y | 19.3% |
| Sales | 5.82B | P/B | 3.69 | EPS next 5Y | 10.02% | ROA | 23.55% | Short Interest | 10.03M | Perf YTD | 18.05% |
| Book/sh | 31.57 | P/C | 5.21 | EPS past 3/5Y | 61.53% - | ROE | 30.67% | 52W High | -12.07% ($132.60) | Perf Year | 25.27% |
| Cash/sh | 22.38 | P/FCF | 12.31 | Sales past 3/5Y | 14.84% 14.03% | ROIC | 25.3% | 52W Low | 38.78% ($84.02) | Perf 3Y | 121.93% |
| Dividend Est. | - | EV/EBITDA | 9.87 | EPS Y/Y TTM | 80.66% | Gross Margin | 91.42% | Volatility(W/M) | 2.88% 2.81% | Perf 5Y | 79.47% |
| Dividend TTM | - | EV/Sales | 3.29 | Sales Y/Y TTM | 26.93% | Oper. Margin | 31.61% | ATR (14) | 3.4 | Perf 10Y | 34.01% |
| Dividend Ex-Date | - | Quick Ratio | 4.51 | EPS Q/Q | 38.02% | Profit Margin | 27.71% | RSI (14) | 50.22 | Recom | 2.29 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.59 | Sales Q/Q | 37.72% | SMA20 | 2.13% ($114.17) | Beta | 0.79 | Target Price | $131.43 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/10/29 | SMA50 | -3.63% ($120.99) | Rel Volume | 1.3 | Prev Close | $113.31 |
| Employees | 2844 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 40.72% 11.31% | SMA200 | 8.09% ($107.87) | Avg Volume(3M) | 1.67M | Price | $116.6 |
| IPO | 1993/11/4 | Option/Short | Yes/Yes | Trades | 25741 | Volume | 2,180,574 | Change | 2.9% |
🧬 A biotech company that develops and sells innovative new drugs in the fields of hematologic cancers, oncology, and skin diseases. Its key product is Jakafi (ruxolitinib), a treatment for myelofibrosis, along with Opzelura, a topical treatment for skin diseases, and a pipeline spanning oncology and immunology. It is a representative biotech company with its own drug discovery and development capabilities.
Over the past 1 year, roughly in the middle
12% below its 1-year high.
Traded more than usual. That is 130% of its average volume.
Next earnings report: October 29
1 days to go.
INCY makes money exceptionally well
Of every $100 in sales, $31.61 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -56.2% this year.
Tap to view numbers
Within its industry, it looks cheap
For a company earning $100 a year, you would pay $1,486. Peers typically go for $3,476. Compared with its own 5-year average, it is 20% cheaper now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +79.5%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 103.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #11 of 594 in the industry
Based on market cap of $24B.
GMAB#9 Genmab ADR $27B PER 35.4 
ROIV#10 Roivant Sciences Ltd $26B PER - INCY#11 Incyte Corp $24B PER 14.9 
BNTX#12 BioNTech SE ADR $22B PER - 
INSM#13 Insmed Inc $21B PER - 
FAQ
What kind of company is INCY?
INCY belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of INCY?
The market cap of INCY is approximately $23.6B, ranking 542 within its sector.
What is the P/E ratio of INCY?
INCY has a P/E ratio of approximately 14.9x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for INCY?
INCY has recorded a 52-week high of $132.60 and a low of $84.02.
